PLoS One
October 26, 2017
Grace E. Fox, Meng Li, Fang Zhao et al.
Ketamine is known to induce psychotic-like symptoms, including delirium and visual hallucinations. It also causes neuronal damage and cell death in the retrosplenial cortex (RSC), an area that is thought to be a part of high visual cortical pathways and at least partially responsible for ketamine’s psychotomimetic activities. However, the basic physiological properties of RSC cells as well as...
Journal of Psychopharmacology
October 17, 2017
Mark J. Niciu, Nicolas D. Iadarola, Dipavo Banerjee et al.
23 citations
BACKGROUND: This study sought to reproduce, in a larger sample, previous findings of a correlation between smaller raw 3-Tesla (3T) hippocampal volumes and improved antidepressant efficacy of ketamine in individuals with major depressive disorder (MDD). A secondary analysis stratified subjects according to functional BDNF rs6265 (val66met) genotype. METHODS: Unmedicated subjects with...
Journal of Affective Disorders
October 15, 2017
David Feifel, Benjamin Malcolm, Danielle Boggie et al.
Recent studies demonstrating a rapid, robust improvement in treatment resistant depression (TRD) following a single sub-anesthetic infusion of ketamine have generated much excitement. However, these studies are limited in their generalizability to the broader TRD population due to their subject exclusion criteria which typically limit psychiatric comorbidity, concurrent medication, and level of...
Molecular Psychiatry
October 3, 2017
Michelle Kokkinou, Abhishekh Hulegar Ashok, Oliver Howes
252 citations
Ketamine is a non-competitive antagonist at the N -methyl- d -aspartate receptor. It has recently been found to have antidepressant effects and is a drug of abuse, suggesting it may have dopaminergic effects. To examine the effect of ketamine on the dopamine systems, we carried out a systematic review and meta-analysis of dopamine measures in the rodent, human and primate brain following acute...
American Journal of Psychiatry
October 3, 2017
S. Wilkinson, Elizabeth D. Ballard, Michael H. Bloch et al.
680 citations
Objective Suicide is a public health crisis with limited treatment options. We conducted a systematic review and individual participant data meta-analysis examining the effects of a single dose of ketamine on suicidal ideation. Method Individual participant data were obtained from 10 of 11 identified comparison intervention studies (using either saline or midazolam as control). The analysis...
Behavioural Pharmacology
October 1, 2017
José E. Suárez-Santiago, Alfredo Briones-Aranda, Judith Espinosa-Raya et al.
Major depression is one of the most common affective disorders caused by schizophrenia. The administration of N-methyl-d-aspartate receptor antagonists, such as ketamine, can reproduce the negative and affective symptoms of this disorder in animals. Preclinical studies have shown that 5-HT6 receptor (5-HT6R) agonists and antagonists have a considerable antipsychotic response. The aim of the...
Psychopharmacology
October 2017
Jingyi Ma, L Stan Leung
Decreased GABAB receptor function is proposed to mediate some symptoms of schizophrenia. In this study, we tested the effect of CGP7930, a GABAB receptor positive allosteric modulator, on ketamine-induced psychosis-relevant behaviors and hippocampal electrical activity in behaving rats. Electrodes were bilaterally implanted into the hippocampus, and cannulae were placed into the lateral...
Contemporary nurse
October 2017
Michael Neufeld, Deborah Spence, Tineke Water
Physiological risks of ketamine have been well researched, yet for health professionals (HPs) undertaking paediatric ketamine sedation, questions of benefit and harm remain. What are health care professionals' experiences of undertaking ketamine sedation with children? Hermeneutic narrative. The study comprised hermeneutic narrative analysis of stories from seven HPs in nursing, medicine,...
Journal of Psychopharmacology
October 2017
Paul Glue, Natalie J. Medlicott, Sarah Harland et al.
The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
October 2017
Chadi G. Abdallah, Christopher L. Averill, Ramiro Salas et al.
Prefrontal global brain connectivity with global signal regression (GBCr) was proposed as a robust biomarker of depression, and was associated with ketamine's mechanism of action. Here, we investigated prefrontal GBCr in treatment-resistant depression (TRD) at baseline and following treatment. Then, we conducted a set of pharmacological challenges in healthy subjects to investigate the...